Peripheral T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Peripheral T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-07-15Clinical Trial Update: Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma [Phase 2]
Phase 2 clinical trial update for E7777 in relapsed or refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma has completed rec…
-
CLINICAL_TRIALS trial_result · 2021-05-20Clinical Trial Update: CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma [Phase 2]
Phase 2 clinical trial update for CC486-CHOP in patients with previously untreated peripheral T-cell lymphoma has completed with results pos…
-
CLINICAL_TRIALS trial_result · 2021-05-11Clinical Trial Update: Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study [Phase 3]
Phase 3 clinical trial evaluating cladribine with BEAC pretreatment in peripheral T-cell lymphoma; efficacy and safety results not yet avail…
-
CLINICAL_TRIALS trial_result · 2021-04-21Clinical Trial Update: CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma [Phase 2]
Phase 2 trial of CD4 in combination with CHOP for non-cutaneous peripheral T-cell lymphoma was terminated.
-
CLINICAL_TRIALS trial_result · 2021-03-09Clinical Trial Update: Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL [Phase 2]
Phase 2 trial update investigating sintilimab with chidamide and azacitidine for refractory or relapsed peripheral T-cell lymphoma.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-03-03Clinical Trial Update: Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226) [Phase 2]
Phase 2 trial update for GB226 in Chinese patients with relapsed/refractory peripheral T cell lymphoma (PTCL).
-
CLINICAL_TRIALS trial_result · 2021-01-19Clinical Trial Update: Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) [Phase 1, Phase 2]
A phase 1/2 clinical trial investigating the combination of ixazomib and romidepsin in peripheral T-cell lymphoma is currently active but no…
-
CLINICAL_TRIALS trial_result · 2021-01-12Clinical Trial Update: A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma [Phase 2]
Phase 2 clinical trial update for YY-20394 in relapsed or refractory peripheral T-cell/NK-cell lymphoma (PTCL).
-
CLINICAL_TRIALS trial_result · 2020-12-29Clinical Trial Update: Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 [Phase 2]
Phase 2 extension study of mogamulizumab (KW-0761) for Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma in patients who relapsed aft…
-
CLINICAL_TRIALS trial_result · 2020-12-29Clinical Trial Update: Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 safety study of the monoclonal antibody mogamulizumab (KW-0761) in subjects with peripheral T-cell lymphoma has completed, with …
-
CLINICAL_TRIALS trial_result · 2020-11-04Clinical Trial Update: A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL） [Phase 2]
Phase 2 trial update for TQ-B3525 in relapsed/refractory peripheral T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2020-10-22Clinical Trial Update: The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL). [Phase 2]
Phase 2 trial update evaluating the efficacy and safety of F520 in patients with relapsed/refractory Peripheral T Cell Lymphoma.
-
CLINICAL_TRIALS trial_result · 2020-10-22Clinical Trial Update: Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL [Phase 2]
Phase 2 trial update comparing CHOP versus fractionated ICED in transplant-eligible, untreated peripheral T-cell lymphoma patients.
-
CLINICAL_TRIALS trial_result · 2020-09-23Clinical Trial Update: Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma [Phase 2]
A Phase 2 clinical trial reports results on the HCVIDDOXIL regimen for newly diagnosed peripheral T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2020-07-14Clinical Trial Update: A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma [Phase 2]
Phase 2 clinical trial update for SHC014748M in relapsed or refractory Peripheral T Cell Lymphoma.
-
CLINICAL_TRIALS trial_result · 2020-06-16Clinical Trial Update: Lenalidomide in Combination With CHOP in Patients With Untreated PTCL [Phase 1, Phase 2]
Clinical trial update for lenalidomide plus CHOP in untreated peripheral T-cell lymphoma (PTCL) across early phases; status not specified.
-
CLINICAL_TRIALS trial_result · 2020-05-12Clinical Trial Update: PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma [Phase 4]
A Phase 4 clinical trial update involving a PD-1 antibody combined with chidamide, lenalidomide, and gemcitabine for peripheral T-cell lymph…
-
CLINICAL_TRIALS trial_result · 2020-04-27Clinical Trial Update: Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) [Phase 2]
A Phase 2 trial evaluating aggressive induction therapy followed by autologous stem cell transplantation using denileukin diftitox (Ontak) f…
-
CLINICAL_TRIALS trial_result · 2020-04-24Clinical Trial Update: Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma [Phase 2]
Phase 2 trial evaluating chidamide in combination with lenalidomide for relapsed or refractory peripheral T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2020-04-21Clinical Trial Update: Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma [Phase 2]
Phase 2 trial investigating nivolumab for relapsed or refractory peripheral T-cell lymphoma is terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2020-03-23Clinical Trial Update: Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating everolimus and lenalidomide in relapsed or refractory non-Hodgkin or Hodgkin lymphoma; results posted.
-
CLINICAL_TRIALS trial_result · 2020-03-18Clinical Trial Update: A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma [Phase 2]
Phase 2 trial of ONTAK with CHOP in newly diagnosed peripheral T-cell lymphoma completed; results posted.
-
CLINICAL_TRIALS trial_result · 2020-03-10Clinical Trial Update: CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL [Phase 2]
Phase 2 trial comparing CEOP/IVE/GDP to CEOP as first-line therapy for adults with peripheral T-cell lymphoma subtypes; status currently unk…
-
CLINICAL_TRIALS trial_result · 2020-01-13Clinical Trial Update: Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma [Phase 1]
Phase 1 trial assessing safety and efficacy of a dual PI3K Delta/Gamma inhibitor in T-cell lymphoma types; study completed with posted resul…
-
CLINICAL_TRIALS trial_result · 2019-11-20Clinical Trial Update: Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies [Phase 2]
Phase II study of Folotyn with leucovorin to prevent or reduce mucositis in patients with relapsed or refractory peripheral T-cell lymphoma …